Nivolumab and rHuPH20 is named as a drug or biological intervention in 2 clinical trials in our USA and Ireland trial registers, 1 of which is recruiting. The lead sponsor is Bristol-Myers Squibb. Registered phases: Phase 3 and Phase 1/2. Conditions studied include Clear Cell Renal Cell Carcinoma; Advanced Solid Tumors.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors |
Phase 1/2 | Recruiting |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (ClinicalTrials.gov ↗) Clear Cell Renal Cell Carcinoma |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Clear Cell Renal Cell Carcinoma | 1 |
| Advanced Solid Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 2 |
| Register | Nivolumab and rHuPH20 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in Ireland | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nivolumab and rHuPH20 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nivolumab and rHuPH20 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.